An interventional study of Restrata® and Wound Dressing in Diabetic Foot Ulcer, sponsored by Acera Surgical, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Acera Surgical, Inc. (part of Solventum) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Diabetic Foot by Solventum — none open to participants now, none under way, none of them phase 3. Diabetic Foot · Solventum.
Among the 12 studies in Diabetic Foot by Solventum, this one is one of 2 that started in 2021, is one of 8 with no phase, and was the 11th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →None of the 12 studies in Diabetic Foot by Solventum is open now. The open studies under Diabetic Foot, anywhere →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2021.
This study's enrollment of 46 is below the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Median enrollment 48 across the 9 interventional studies, 135 across the 3 observational. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acera Surgical, Inc., one of the names counted as Solventum. Under that name alone:
Acera Surgical, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Diabetic Foot by Solventum, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the following prospective, randomized, controlled clinical trial is to compare synthetic hybrid-scale fiber matrix (Restrata®, Acera Surgical, Inc.) with standard of care in treating diabetic foot ulcers in human subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has adequate circulation to the affected extremity, as demonstrated by at least ONE of the following within 60 days prior to enrollment/randomization:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diabetic foot ulcers will be treated by application of the Synthetic Hybrid-Scale Fiber Matrix. The synthetic matrix will be applied weekly or as needed based on the clinician discretion and ongoing wound assessment.
Device: Restrata®
Diabetic foot ulcers will be treated by application of an appropriate dressing (foam or alginate dressing) to maintain wound moisture balance in the wound and changed daily.
Device: Wound Dressing
Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.
Also known as: Synthetic Hybrid-Scale Fiber Matrix
Alginate or Foam wound dressing is intended to manage wounds.
Number of Participants With 100% Re-epithelialization
Primary outcome is number of participants with 100% epithelialization at 12 weeks of treatment as determined by investigator assessment of the ulcer and imaging.
Time frame: 12 weeks
Change in Wound Area
The difference in wound area from baseline to 100% re-epithelialization or week 12 will be summarized for each treatment group in each arm. Wound sizes were documented by the investigator at baseline to end of the treatment period for each participant.
Time frame: 12 weeks
Time to Wound Closure
The number of weeks from initial application of study treatment until complete re-epithelialization is first identified.
Time frame: Up to 12 Weeks
Number of Treatment Applications
The number of study treatment applications including the initial application until 12 weeks or until complete re-epithelialization, whichever occurs first.
Time frame: 12 weeks
Quality of Life - SF-36
The survey will be completed at the day of initial application and at either 12 weeks or at complete re-epithelialization
Time frame: 12 weeks
Cost Effectiveness / Economic Model
Cost data from the patient's treatment will be analyzed based on diagnoses, procedure and supply codes to determine cost efficacy and outcomes with the treatment pathway and related technology utilized during the course of care.
Time frame: 12 weeks
Incidence of Adverse Events
Time frame: 12 weeks
| Milestone | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care |
|---|---|---|
| Started | 25 | 21 |
| Completed | 19 | 18 |
| Not completed | 6 | 3 |
| Withdrew: Amputation - no longer eligible | 1 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Patient non-compliance | 3 | 1 |
| Withdrew: Adverse event | 1 | 0 |
Primary outcome is number of participants with 100% epithelialization at 12 weeks of treatment as determined by investigator assessment of the ulcer and imaging.
| Participants | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care |
|---|---|---|
| Number of Participants With 100% Re-epithelialization | 14 | 6 |
The difference in wound area from baseline to 100% re-epithelialization or week 12 will be summarized for each treatment group in each arm. Wound sizes were documented by the investigator at baseline to end of the treatment period for each participant.
| Percentage of ulcer size decrease | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care |
|---|---|---|
| Change in Wound Area | 89.3 ± 20.8 | 62.9 ± 56.0 |
The number of weeks from initial application of study treatment until complete re-epithelialization is first identified.
| Number of weeks | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care |
|---|---|---|
| Time to Wound Closure | 6.57 ± 3.0 | 7.0 ± 2.9 |
The number of study treatment applications including the initial application until 12 weeks or until complete re-epithelialization, whichever occurs first.
| Average number of treatment applications | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care |
|---|---|---|
| Number of Treatment Applications | 6.8 ± 3.5 | 7.7 ± 3.5 |
The survey will be completed at the day of initial application and at either 12 weeks or at complete re-epithelialization
Results for this outcome have not been posted.
Cost data from the patient's treatment will be analyzed based on diagnoses, procedure and supply codes to determine cost efficacy and outcomes with the treatment pathway and related technology utilized during the course of care.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over For each individual patient, data was collected over the 12 week treatment period or until complete re-epithelialization and 2 week follow up visit, up to a maximum of 14 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment With Synthetic Hybrid-Scale Fiber Matrix | 1/25 (4%) | 2/25 (8%) | 6/25 (24%) |
| Treatment With Standard of Care | 0/21 (0%) | 2/21 (9.5%) | 2/21 (9.5%) |
| Event | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care |
|---|---|---|
| AmputationSkin and subcutaneous tissue disorders | 1/25 | 2/21 |
| Cerebral vascular accidentCardiac disorders | 1/25 | 0/21 |
| Event | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care |
|---|---|---|
| InfectionSkin and subcutaneous tissue disorders | 6/25 | 2/21 |
| Age, Categorical(Participants) | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 10 | 20 |
| >=65 years | 15 | 11 | 26 |
| Sex: Female, Male(Participants) | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care | Total |
|---|---|---|---|
| Female | 8 | 4 | 12 |
| Male | 17 | 17 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 8 |
| Not Hispanic or Latino | 19 | 19 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment With Synthetic Hybrid-Scale Fiber Matrix | Treatment With Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 21 | 17 | 38 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2021 to primary completion in Jul 2022, 14 months.
Results were first posted in Sep 2023, 1 year 1 month after primary completion.
Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 14 months is below that.
Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.